In the study, researchers
randomly assigned patients to one of three groups. In all three groups,
patients received peginterferon and ribavirin (the current standard of
care) for four weeks.

The heptalogist at California Pacific Medical Center was part of
helping Vertex receive Federal Drug Administration approval Monday for
Incivek, a “groundbreaking” drug that doubles the chance of curing
hepatitis C cases (up from 40 to 80 percent).
What does the drug do? Incivek
is a drug that works directly on the virus and it helps to prevent
replication of the virus. ... It marks a turning point in the treatment
of hep C, which kills 5,000 to 12,000 Americans a year.